Live Breaking News & Updates on Event Free Survival

Stay updated with breaking news from Event free survival. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications. ....

Elias Jabbour , First Report , Comparing Ponatinib , Newly Diagnosed , Acute Lymphocytic Leukemia , Call Cancer , All Leukemia , Ph Positive , Oph All , Tyrosine Kinase Inhibitors , Tki Therapy , Combination Therapy , Bcr Abl , Ponatinib Dose , Ponatinib Dosing , Complete Response , Survival Data , Adverse Events , Drug Adverse Event , Mrd Negativity , Mrd Negative , Duration Of Response , Crossover Therapy , Sequencing Therapy , Event Free Survival , Efs Data ,

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting. ....

Neoadjuvant Durvalumab , John Heymach , Adjuvant Durvalumab , Partnership With , Non Small Cell Lung Cancer , Early Stage Lung Cancer , Early Stage Nsclc , Durvalumab Therapy , Overall Survival , Progression Free Survival , Event Free Survival , Pathologic Complete Response , Pd L1 Expression , Pd L1 Level , Adverse Events , Drug Adverse Event , Aegean Study , Aegean Trial , Efs Bicr , Dfs Bicr ,

Actinium Pharma (ATNM) Highlights First-In-Class HER3 Targeted Radiotherapy Data

Actinium Pharma (ATNM) Highlights First-In-Class HER3 Targeted Radiotherapy Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Hans Vitzthum , Development Agreement , Astellas Pharma Inc , Epicentrx Inc , Actinium Pharmaceuticals Inc , Oncology Inc , Memorial Sloan Kettering Cancer Center , American Association For Cancer Research , National Cancer Institute , Lifesci Advisors , American Association , Cancer Research , About Actinium Pharmaceuticals , Elderly Relapsed , Refractory Acute Myeloid Leukemia , Complete Remission , Event Free Survival , Acute Myeloid Leukemia , Cooperative Research , Astellas Pharma , Sci Advisors ,

Actinium Pharma (ATNM) Presents Data Demonstrating Actimab-A's Potential

Actinium Pharma (ATNM) Presents Data Demonstrating Actimab-A's Potential
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Sandesh Seth , Hans Vitzthum , Oncology Inc , Epicentrx Inc , National Cancer Institute , Development Agreement , American Association For Cancer Research , Lifesci Advisors , Astellas Pharma Inc , Actinium Pharmaceuticals Inc , Memorial Sloan Kettering Cancer Center , American Association , Cancer Research , Non Small Cell , Actinium Pharmaceuticals , Elderly Relapsed , Refractory Acute Myeloid Leukemia , Complete Remission , Event Free Survival , Acute Myeloid Leukemia , Cooperative Research , Astellas Pharma , Sci Advisors ,

Immunotherapy improves lung cancer outcomes

Immunotherapy given before and after surgery significantly improved outcomes in patients with operable non-small cell lung cancer. ....

United States , Elissa Wolfson , John Heymach , University Of Texas , American Association For Cancer Research , Science Advisory Board , American Association , Cancer Research , Lung Cancer , Non Small Cell Lung Cancer , Esectable Cancer , Platinum Based Chemotherapy , Djuvant Placebo , Pathologic Complete Response , Event Free Survival , University Of Texas Md Anderson Cancer Center , American Association For Cancer Research ,